Basic Synthroid Information

• INN (International Nonproprietary Name): Levothyroxine sodium.
• Brand Names Available In Canada (English): Synthroid and Eltroxin are listed as available brands in Canada.
• ATC Code: H03AA01 — systemic hormonal thyroid preparations; synthetic thyroxine (T4).
• Forms & Dosages: Oral tablets in multiple strengths (examples: 25, 50, 75, 88, 100, 112, 125, 137, 150, 175, 200, 300 mcg). Oral liquid formulations exist in select markets (examples: 25 mcg/mL, 50 mcg/mL) but availability in Canada may be limited.
• Manufacturers In Canada (English): Not specified in the supplied dataset for Canada-specific manufacturers; global manufacturers include AbbVie (Synthroid) and multiple generic suppliers.
• Registration Status In Canada (English): Not specified in the supplied dataset for Canadian regulatory listings; approvals are documented for FDA (US) and EMA (EU) in the source material.
• OTC / Rx Classification: Prescription only (Rx) in all countries referenced in the source data.
• Typical Adult Dosages: Initial replacement often starts at 25–50 mcg once daily, titrated every 4–6 weeks based on TSH. Full replacement commonly approximates 1.6 mcg/kg/day once daily.
• Dosing Notes For Special Populations: Neonates and children require weight‑based dosing (examples in source: 10–15 mcg/kg/day for neonates with severe hypothyroidism). Elderly patients typically start lower (12.5–25 mcg/day) because of cardiovascular sensitivity.
• Storage & Transport: Store 20–25°C (68–77°F), protect from light, moisture and heat; transport in original packaging to preserve potency.
• Contraindications: Absolute contraindications listed in the source data include untreated thyrotoxicosis, untreated adrenal insufficiency, recent/ongoing acute myocardial infarction, and hypersensitivity to levothyroxine or excipients.
• Common Side Effects: Mild — headache, nervousness, insomnia, mild tremors, increased appetite, weight loss. Moderate/notable — palpitations, tachycardia, increased blood pressure, heat intolerance, diarrhea, menstrual changes; most adverse effects reflect over‑replacement (hyperthyroidism).

Latest Research Highlights

Patients often ask whether brand name synthroid performs differently than generics.

Recent literature has emphasised comparative trials and real‑world reports about brand versus generic stability, though specific 2022–2025 trial names are not listed in the supplied product dataset.

Clinical discussion points include patient‑reported symptoms persisting despite biochemical euthyroidism and careful pregnancy dosing adjustments during gestation.

Liquid levothyroxine formulations have been highlighted internationally for use when oral absorption is compromised, for example with malabsorption or when patients cannot take tablets.

Health Canada–aligned guidance generally supports consistent therapeutic effect when formulation and regimen remain stable.

US and EU practice notes in the source data call out tablet colour‑coding and careful interchangeability procedures to reduce dispensing errors and clinical variability.

Insert table suggestion: “Recent Trials 2022–2025” with columns: Study, Country, Design, N, Key Outcome, Implication For Practice.

Data highlights block suggestion: report hypothyroidism prevalence by sex and age in Canada (not specified in this dataset) and note underrepresentation of Indigenous and rural cohorts in published data.

Patient‑centred outcomes meaningful to Canadians include energy levels, cognitive function, and pregnancy outcomes.

• Top 5 Actionable Findings For Clinicians And Pharmacists:
  1. Keep patients on the same product when possible to improve biochemical stability with levothyroxine.
  2. Arrange TSH testing 6–8 weeks after any product or dose change.
  3. Increase monitoring and typically increase dose early in pregnancy to meet gestational needs.
  4. Consider liquid levothyroxine for patients with malabsorption or swallowing issues.
  5. Use tablet colour‑coding and clear labelling to reduce dispensing errors at the pharmacy level.

Clinical Effectiveness In Canada

How effective is levothyroxine for restoring normal thyroid function?

Health Canada–aligned monographs and the ATC classification (H03AA01) describe levothyroxine sodium as a well‑established synthetic T4 replacement with predictable therapeutic effect when dosed and monitored appropriately.

Levothyroxine is prescription‑only across Canada and clinical monitoring focuses on restoring and maintaining a normal TSH.

Definitions

• Levothyroxine sodium: synthetic T4 hormone used for replacement therapy.
• Therapeutic goal: restore and maintain a normal TSH level.
• Monitoring: TSH and, where indicated, free T4 measured about 6–8 weeks after a dose change.

Provincial formularies commonly list levothyroxine products on ODB (Ontario), BC PharmaCare, and RAMQ, but coverage and criteria differ by plan and patient eligibility.

Check DIN‑specific listings in Health Canada’s Drug Product Database for reimbursement details for the exact product supplied.

Insert table suggestion: “Monitoring Schedule And Target Ranges” with rows for adults, pregnancy, and elderly patients showing TSH targets and recommended monitoring intervals.

Clinical effectiveness improves when brand or generic product and dosing schedule remain consistent for the patient.

Counselling is available bilingually at major chains like Shoppers Drug Mart, Rexall, Jean Coutu and London Drugs and supports adherence for Canadian patients.

Indications And Expanded Uses

What is levothyroxine approved to treat in Canada and what are common off‑label uses?

• Approved Indications: Primary hypothyroidism, suppression of goitre, and adjunctive therapy in thyroid cancer management (dose individualized, often TSH suppression).
• Off‑Label/Common Practice Uses: Management of subclinical hypothyroidism in selected patients and neonatal dosing protocols following newborn screening algorithms.

Important safety note: levothyroxine is not indicated for weight loss; Health Canada and international guidance warn against use for obesity because of risk.

Patient examples: pregnant patients typically need higher dosing; postpartum thyroiditis requires follow‑up and tailored therapy; hypothyroidism after thyroidectomy or radioiodine treatment may be transient or lifelong depending on the case.

Insert table suggestion: “Indications And Typical Dosing Ranges” linking condition to starting dose and frequency (for example, starting 25–50 mcg/day in many adults; higher, weight‑based dosing for full replacement).

Special care is required for Indigenous and remote communities where laboratory follow‑up capacity and reliable supply must be ensured to avoid treatment interruptions.

Provincial guidance differs for neonatal screening follow‑up and referral pathways; endocrinology access may be limited in rural settings and telehealth options should be considered.

Composition And Brand Landscape

What is in each pill and which brands are on Canadian shelves?

The active ingredient in all products is levothyroxine sodium.

Common Canadian brands recorded in the provided data include Synthroid and Eltroxin.

Insert table suggestion: “Canadian Product Mix” with columns: Brand, Form, Common Strengths, Manufacturer, Note On DIN Lookup.

Tablet colour‑coding by strength is used internationally and helps reduce dispensing errors; Canadian pharmacies commonly follow labelling and dispensing best practices to mirror that safety measure.

Generics are supplied by multiple manufacturers and interchangeability is generally clinically acceptable when monitoring follows any product switch.

• Formulation Choices And Counselling Points:
  1. Tablets: most commonly available; counsel to take on empty stomach.
  2. Liquid preparations: useful when tablets are not tolerated or absorption is impaired; availability may be limited in Canada.
  3. Discuss excipient sensitivities if a patient reports allergies.

Pharmacy chains and hospital pharmacies often stock both brand and generic options; provincial formularies frequently prefer generics unless a medical exception is granted.

Contraindications And Special Precautions

Who should not take levothyroxine and when should clinicians exercise extra caution?

Absolute Contraindications: untreated thyrotoxicosis, untreated adrenal insufficiency, recent or ongoing acute myocardial infarction, and known hypersensitivity to levothyroxine or excipients.

Relative Cautions: cardiovascular disease (angina, coronary artery disease), diabetes mellitus, osteoporosis risk, the elderly, recent major surgery or acute illness, and pregnancy adjustments.

When To Consult A Specialist:

• Unstable angina or recent MI prior to initiating replacement.
• New onset atrial fibrillation after starting or increasing dose.
• Severe osteoporosis requiring suppression doses.
• Complex polypharmacy with multiple interaction risks.

Definition list suggestion: explain “absolute vs relative contraindication” and “over‑replacement symptoms” in patient materials.

High‑risk groups in Canada include older adults in long‑term care and patients in remote or Indigenous communities who may lack immediate cardiac assessment — arrange baseline ECG and cardiology input as needed.

Health Canada advisories and provincial referral mechanisms are relevant when specialist opinion is required.

Dosage Guidelines

What are practical starting doses and how are they adjusted?

Standard adult starter doses commonly noted are 25–50 mcg once daily, with full replacement approximately 1.6 mcg/kg/day.

Elderly patients usually start lower at 12.5–25 mcg/day to limit cardiac risk.

Insert table suggestion: “Dosing Quick Reference” with rows for neonates, children, adults (normal, elderly, cardiac disease), pregnancy, and thyroid cancer suppression.

• Titration Schedule:
  1. Adjust dose every 4–6 weeks based on TSH.
  2. Allow longer intervals once stable.
  3. In pregnancy, expect and plan for increased dose needs with more frequent TSH monitoring.

Administration advice: take levothyroxine on an empty stomach 30–60 minutes before breakfast and separate from calcium, iron, and many antacids.

When laboratory access is limited in rural settings, discuss realistic follow‑up plans taking local lab turnaround times into account.

Interactions Overview

Which drugs and foods commonly interfere with levothyroxine?

Major interactors include calcium, iron, aluminium‑containing antacids, sucralfate, proton‑pump inhibitors, bile acid sequestrants, oestrogen therapy, certain anticonvulsants, and some antidepressants.

High‑risk timing rules: separate levothyroxine from calcium and iron by about 4 hours and take levothyroxine on an empty stomach.

Food interactions: high‑fibre diets, soy products, and routine breakfast patterns can reduce absorption and affect levels.

Insert table suggestion: “Interaction, Mechanism, Practical Action” listing the common interactors, their mechanism (reduced absorption or altered metabolism), and counselling steps.

Pharmacists should document complete medication histories, especially for patients receiving multiple provincially covered medications, and counsel about timing adjustments to preserve effect.

Be aware that international formulations or compounded products may differ in excipients and could change interaction profiles.

Cultural Perceptions And Patient Habits

What do Canadian patients commonly worry about when prescribed levothyroxine?

Many Canadians trust lab‑driven targets but express anxiety when products change between brand and generic.

Common community feedback channels, including provincial patient groups and online forums, often highlight fatigue despite “normal” TSH and concerns about brand switching.

Quebec’s bilingual expectations mean many Francophone patients prefer counselling and labelling in French; Eltroxin is a familiar name in some communities.

Urban patients often get faster lab turnaround and specialist access, whereas rural and Indigenous patients may face delayed titration and supply challenges.

• Pharmacist‑Led Counselling Points:
  1. Explain that levothyroxine is not a weight‑loss drug.
  2. Reinforce consistent dosing time and separation from interacting supplements.
  3. Encourage TSH checks after any switch or dose change.
  4. Offer bilingual materials when requested.

Strategies for rural patients include longer prescription supplies where clinically appropriate and liaising with provincial drug plans for continuity.

Availability And Pricing Patterns

Where do Canadians find synthroid and what does it cost?

Synthroid and Eltroxin are available in Canadian pharmacies and generics are widely stocked.

Insert small price‑comparison table suggestion with columns: Product, Typical Canadian Retail Price, US Price, Insurance Coverage Note.

Provincial drug plan coverage varies — ODB, BC PharmaCare and RAMQ may list levothyroxine products but plan rules and copays differ; brand coverage sometimes requires special authorisation.

Cross‑border purchasing is complicated by regulatory differences, DIN mismatches and legal/insurance constraints; check Health Canada and provincial guidance before pursuing importation.

Major chains and online Canadian pharmacies can ship to remote communities; cold‑chain logistics are typically not required but original packaging is advised.

Patient strategies: ask about blister packs, adherence packaging, and enrolment in patient assistance programs when cost is a barrier.

In our online pharmacy, synthroid is available with discreet delivery to Canada (English) in 5–14 days; prescriptions remain required by regulation and pharmacists verify prescriptions before dispensing.

Comparable Medicines And Preferences

What are practical alternatives and when might a brand be preferred?

Alternatives stocked in Canada include generic levothyroxine and Eltroxin; internationally available options include Euthyrox, Euthyrox and Levoxyl in some markets.

• Brand vs Generic — Pros And Cons:
  1. Brand: perceived stability, consistent excipients; often costlier.
  2. Generic: lower cost, widely accessible; clinically acceptable when monitoring occurs after switches.

Insert checklist table: “Choosing Product — Clinical Triggers For Preferring Brand” (e.g., prior TSH instability after switching, pregnancy, paediatric needs).

Tablet colour‑coding reduces dispensing errors internationally, but tablet colour and excipients vary by manufacturer, so monitor TSH after any switch and respect patient preference when clinically reasonable.

Pharmacists can submit medical exception requests to provincial formularies when a brand is clinically justified.

FAQ Section

Q: Can I switch between Synthroid and a generic?

A: Yes, but inform your pharmacist and arrange a TSH check about 6–8 weeks after the switch to confirm stability.

• Steps After A Switch:
  1. Tell your pharmacist about prior product and dose.
  2. Schedule TSH testing 6–8 weeks after the new product begins.
  3. Report new symptoms such as palpitations, tremors, or fatigue promptly.

Q: Will this help me lose weight?

A: No. Levothyroxine is not indicated for weight loss and using it without hypothyroidism is unsafe.

Q: What if I missed a dose?

A: Take the dose as soon as you remember unless it is close to the next scheduled dose; do not double up.

Q: Is it covered by my provincial plan?

A: Coverage depends on the provincial plan (ODB, BC PharmaCare, RAMQ) and the specific DIN; ask your pharmacist to check eligibility and special authorisation options.

Insert quick chart suggestion summarising common provincial copay and coverage patterns for patient reference and emphasise bilingual resources and community pharmacy support for patients without a regular family doctor.

Guidelines For Proper Use

What practical checklist should pharmacists and patients follow to get the best result from levothyroxine?

• Key Patient Checklist:
  1. Take levothyroxine 30–60 minutes before breakfast every day.
  2. Avoid calcium, iron and many antacids within 4 hours of dosing.
  3. Maintain the same product brand when possible.
  4. Arrange TSH checks 6–8 weeks after any dose or product change.
  5. Start at a lower dose in elderly or cardiac patients and titrate slowly.

Pharmacist counselling script (brief):

• Verify adherence and the exact product the patient takes.
• Review interacting products and timing rules.
• Confirm pregnancy status or intent and recommend appropriate monitoring.
• Check provincial coverage and DIN before dispensing and advise on supply continuity for rural patients.

Insert table suggestion: “When To Refer To Endocrinology” (persistent abnormal TSH despite adherence, unstable symptoms, paediatric/neonatal cases, need for high‑dose suppression in thyroid cancer).

Supply continuity tips for rural patients: consider longer prescription runs where clinically appropriate, use mail‑order services from major chains, and liaise with provincial drug plans for emergency supply authorisations.

Authority note: counselling and monitoring recommendations align with Health Canada classification and accepted clinical dosing and monitoring practice from authoritative sources.

Delivery Across Canada (English)